Oncolytic Virus clinical trials

Explore recruiting oncolytic virus clinical trials.

Recruiting oncolytic virus studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oncolytic Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Oncolytic virus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in the treatment of melanoma

Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides in combination with the immunotherapy drug pembrolizumab in patients with injectable solid tumors in defined indications

Germany, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Oncolytic Virus trials by city

Oncolytic Virus in Toronto Oncolytic Virus in Vancouver Oncolytic Virus in Montreal Oncolytic Virus in Calgary Oncolytic Virus in Edmonton Oncolytic Virus in Ottawa Oncolytic Virus in Winnipeg Oncolytic Virus in Quebec City Oncolytic Virus in Hamilton Oncolytic Virus in Kitchener Oncolytic Virus in London Oncolytic Virus in Halifax Oncolytic Virus in New York Oncolytic Virus in Los Angeles Oncolytic Virus in Chicago Oncolytic Virus in Houston

Oncolytic Virus clinical trials

Recruiting oncolytic virus studies right now

Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor

PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases

OH2 Oncolytic Viral Therapy in Solid Tumors

Also recruiting in Europe

Oncolytic virus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in the treatment of melanoma

Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides in combination with the immunotherapy drug pembrolizumab in patients with injectable solid tumors in defined indications

Oncolytic Virus trials by city

Other conditions